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Rapid and accurate diagnosis of meningitis/encephalitis (M/E) is essential for successful
patient outcomes. The FilmArray meningitis/encephalitis Panel (MEP) is a multiplexed
PCR test for simultaneous, rapid detection of pathogens directly from cerebrospinal fluid
(CSF) samples. 94 prospectively collected CSF specimens from patients with clinical sus-
picion of infective M/E underwent testing for 14 pathogens simultaneously, including
Escherichia coli, Haemophilus influenzae, Neisseria meningitidis, and Varicella zoster.
MEP demonstrated 95% agreement with current PCR methods, resulting in 16 diagnosed
cases of M/E. Typically, the FilmArray MEP results were delivered within approximately
one hour, contrasting with current practices taking up to 5.6 days. Given the significant
morbidity and mortality associated with delayed diagnosis of central nervous system
infections, the FilmArray MEP is a useful addition to the diagnostic capabilities of a
clinical microbiology department.
ª 2020 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Despite the introduction of vaccine immunisation programs
worldwide during the 1970s, morbidity and mortality associated
with meningitis or encephalitis (M/E) continue to remain excep-
tionally high. Potentially caused by bacteria, viruses,ical School University of
Dunne).
Elsevier Ltd on behalf of The
ivecommons.org/licenses/by-mycobacteria or, on occasion, fungi [1,2] those at increased risk
of infection include babies <18 months, pre-school children
under the age of 5, teenagers/young adults and also immuno-
compromised patients. Unfortunately, 30e50% of M/E cases
progress to serious complications including hearing and/or speech
loss, blindness, permanent brain or nerve damage, seizures and
loss of limbs [3]. Streptococcus pneumoniae, Neisseria meningi-
tidis and Haemophilus influenzae have in the past been reported
as the most frequent causative agents [4]. Over 1.2 million casesHealthcare Infection Society. This is an open access article
nc-nd/4.0/).
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[2] with, for instance, the Meningitis Research Foundation UK [5]
reporting an estimated 3,200 cases of bacterial meningitis
annually between years 2000e2012. However, viral meningitis is
more common, albeit that many cases go unrecognised and
undiagnosed due to mild, sometimes flu like symptoms.
A diagnosis of M/E is dependent upon both clinical pre-
sentation of the patient and laboratory analysis of cere-
brospinal fluid (CSF). However, according to Hanson [6]
reaching an accurate diagnosis can be complex as clinical signs
and symptoms associated with M/E are not organism specific
and, therefore, differential diagnosis can be broad. Culturing
and Gram stain have been described as the optimal tests
(currently available) for the diagnosis of bacterial and fungal
meningitis, with PCR methods most accurate for detecting viral
meningitis [4,7e9]. However for bacterial and fungal menin-
gitis, both conventional microbiology and PCR tests are prone
to confounders whereby antimicrobial treatment prior to CSF
sampling and slow growth rate of some pathogens can jeop-
ardise or delay accurate diagnosis. Prior to introduction of the
FilmArray MEP, CSF samples had been referred for viral PCR
where any suspicion of viral M/E existed, even in the absence of
CSF pleocytosis. Additionally, when polymorphonuclear cells
represented >50% WBCs, bacterial polymerase chain reaction
(PCR) was performed on the CSF samples. Viral PCR was per-
formed when mononuclear cell dominated. Although 600e700
CSF samples are processed annually in our diagnostic service,
such PCR testing is outsourced to the central Irish Meningo-
coccal and Sepsis Reference Laboratory (IMSRL) or the central
National Virus Reference Laboratory (NVRL). Concern arose in
our service due to delays in obtaining results of referred PCR
tests; specifically, in the context of timely diagnosis being
required to enable targeted antimicrobial therapy for con-
firmed bacterial M/E (rather than empiric intravenous/intra-
muscular benzyl penicillin or cephalosporin) or, more
commonly, discharge from hospital and discontinuation (where
appropriate) of therapy for viral M/E patients.
Ireland has the highest rate of meningococcal meningitis in
Europe with almost 200 cases reported annually [5]. Therefore,
our study aimed to assess a rapidmolecular method of diagnosis
that could be implemented locally and lessening reliance on
centralised national laboratories.More precisely,weperformed
a comprehensive evaluation of the FilmArray multiplex PCR
system (FA) with FilmArray Meningitis/Encephalitis panel
(MEP) [10] to determine its impact in the diagnosis of M/E, when
introduced routinely in our microbiology laboratory. Emphasis
was placed on: [1] validation of the FilmArray MEP for detec-
tionof 14 commonCSFpathogens includingbacteria, viruses and
yeast; [2] assessment of the sensitivity of the FilmArray com-
pared to conventional methods performed in house, in con-
junction with qualitative PCR assays completed at central
national laboratories; [3] determination of M/E diagnosis turn-
around time (TAT); and [4] retrospective chart review-based
calculation of cost-effectiveness of FilmArray introduction.Methods
Setting and inclusions
The study was performed at University Hospital Limerick in
Ireland’s mid-West; a 480-bed tertiary hospital for a populationof > 600,000. The microbiology diagnostic service processes
between 600 and 700 CSF samples annually. This assessment
was performed over a 5 month period (MarcheJuly; due to
availability of FilmArray MEP products for that period) during
which a minimum of 97 samples would be required due to a
calculated margin of error of 8% and confidence level of 95%.
CSF samples were eligible for inclusion if submitted for testing
due to clinical suspicion of an infective M/E, a raised Leucocyte
count (>5/ml) was noted on microscopy, or viral PCR was
requested. To establish the sensitivity of the FilmArray MEP,
CSF samples that had previously been confirmed positive by the
reference laboratories were frozen and stored at e 20oC prior
to the six-month testing period (Dec 2016eMarch 2017). Those
samples were analysed subsequently by FilmArray MEP and
outcomes compared to the PCR results obtained when the same
samples were tested by the accredited reference laboratory.
Non-FilmArray MEP CSF protocol
Macroscopic appearance of each CSF sample was described
(clear, cloudy, bloodstained, yellow, turbid or clotted). Leu-
cocytes and erythrocytes were quantified by manual micro-
scopy using a KOVA Glasstic Slide counting chamber in which
1ml of CSF was assessed using manual light microscopy. Un-
centrifuged samples were inoculated on both 5% sheep blood
agar (Oxoid) and chocolate agar (Oxoid) and incubated in 5%
CO2 at 35e37. An additional blood agar plate was cultured and
incubated anaerobically. All plates were incubated for 48 hours
and also reviewed subsequent to overnight incubation. All CSF
samples with a white cell count >5 leucocytes/ml underwent
Gram stain and a differential white blood cell count. Where
microbes were observed, a Meningitis Latex Agglutination Test
(Pasteurex) was performed for identification of N. meningitidis
A, B, C, Y and W135; E. coli K1; H. influenzae Type b,
S. pneumoniae or S. agalactiae. Differential slides were pre-
pared by spinning 200 ml of CSF sample at 1000 rpm for 5
minutes using an Aerospray cytocentrifugation slide stainer.
The slides were processed with Wright-Giemsa stain using a
Hematek slide stainer (Siemens) and the ratio of poly-
morphonuclear cells to mononuclear cells recorded. CSF Sam-
ples with a cell count of >5/ml and >50% polymorphonuclear
leucocytes were referred to the IMSRL for bacterial PCR testing
targeting; N. meningitidis, S. pneumonia, S. agalactiae,
H. influenzae and E. coli K. CSF samples with a cell count>5/ml
and >50% mononuclear leucocytes, or where specifically
requested, were referred to the National Viral Reference
Laboratory for viral PCR targeting Herpes simplex virus 1,
Herpes simplex virus 2, Varicella zoster virus and Human her-
pes virus 6. In cases where Cryptococcus neoformans was tes-
ted for, the Cryptococcal Antigen Lateral Flow Assay (LFA) was
used. For our prospective comparison, all CSF samples referred
for external PCR underwent parallel processing using the
FilmArray MEP.
FilmArray MEP protocol
Processing was performed as per manufacturer’s instruc-
tions. In summary, approx. 200 ml CSF is lysed using buffers
provided prior to qualitative PCR using proprietary primers on
the in vitro FilmArray Multiplex PCR analyser. The entire PCR
process occurs within one pouch and takes approx. 1 hour from
start to completion. The process involves nucleic acid
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2nd stage nested PCR and DNA Melting Analysis 10).
Quality procedures
For validation, 94 prospective patient CSF samples were run
on both the FilmArray MEPl and the current routine methods
of microscopy/Gram stain culture. Samples were also referred
to reference laboratories for both bacterial and viral PCR as
part of the quality control programme. Retrospective samples
that had been frozen were also run on the FilmArray MEP and
the results compared to reference reports. All targets on the
FilmArray MEP were detected by 3 methods: 1) true positive
samples; 2) control samples received from the NVRL arising
from other hospital sites; and 3) the recommended
ZeptoMetrix validation panel controls. Positive/negative
controls could not be run each time as the platform has a low
sample throughput. However, the assay includes an internal
quality control including a RNA process control. The latter
targets an RNA transcript from the yeast Schizosaccharomyces
pombe. The yeast was present in the pouch in a freeze-dried
form and becomes rehydrated when sample is loaded. The
control material is carried through all stages of the test proc-
ess, including lysis, nucleic acid purification, reverse tran-
scription, 1st stage PCR, dilution, 2nd stage PCR and DNA
melting. A positive control result indicates that all steps per-
formed in the FilmArray ME pouch were successful. Therefore,
if there is an RNA process control failure, all steps were not
completed successfully and a result cannot be accepted.
Retrospective chart review and economic analysis
A retrospective chart review of paediatric patients who had
CSF samples analysed in the six months prior to the availability
of FilmArray MEP was performed to evaluate potential
improved turnaround time (TAT) of results and diagnosis. This
was compared with actual length of stay and treatment of
patients following introduction of the FilmArray.
Potential cost-savings were deduced from potential reduc-
tion in duration of hospitalisation and reduction in duration of
empirical antimicrobial/antiviral therapy. The overall cost of
the FilmArray MEP multiplex PCR in terms of material and
labour was based on actual cost for 94 tests. The scientist rate
of pay was established from the median of the basic grade
medical scientist rate in Ireland, so again is based on actual
costs.
Statistical analysis
All statistical analysis was performed using IBM SPSS Sta-
tistics 24.
Levene’s test for equality of variance was used when
determining significant difference in length of stay (LOS) in the
paediatric cohort pre- and post-introduction of the FilmArray
MEP. An independent samples t-test for equality of means was
utilised to determine significance in variation between length
of hospital stay before and following the intervention.
The FilmArray MEP test runetime was compared to the
time taken for return of reference laboratory reports to
establish the difference in test TAT and to determine the use-
fulness of the FilmArray MEP for timely diagnosis. One sam-
ple t-test analysis was used.Results
Comparison of testing pre- and post-FilmArray use
The manufacturer of the BioFire FilmArray MEP state
that the limit of detection (LOD) is 100e1,000 CFU/ml for
all bacteria & yeast, and 5e500 Tissue Culture Infective
Dose (TCID) 50/ml or 100e1,000 copies/ml for all viruses,
which was utilised as the LOD for this study [11]. Pro-
spective analysis using the FilmArray MEP was attempted
in 100 CSF samples. However, 6 were discarded due to RNA
process control failure (1 sample), insufficient sample vol-
ume for referral to reference laboratories and therefore no
comparison was possible (3 samples), and false positive
contamination (2 samples). The latter were confirmed as
negative when re-run on the FilmArray MEP and found to
be PCR negative when referred to the Reference Lab.
Overall, the FilmArray demonstrated sensitivity and specif-
icity analogous to that of the PCR-based bacterial reference
laboratory, but was less sensitive with regard to virus sen-
sitivity (86%).Turnaround time and impact on length of stay
When compared, the mean TAT using the FilmArray MEPas
70 mins versus a mean time of 135 hrs 40 mins for communi-
cation of results from the reference laboratories. The average
time taken for the return of reference laboratory reports was
about 134 hours longer (5.6 days) than the average time taken
to run a FilmArray analysis (1.167 hours). The one sample
tetest demonstrated (p <0.05) rejection of the null hypothesis
indicating that the introduction of the FilmArray MEP
improved the TAT for diagnosis of M/E, due to reduction in
mean sample test processing time.
Comparison of 18 retrospective charts and 16 prospective
charts was performed. Improvement in availability of test
results was associated with statistically significant shortening
of hospitalization. Specifically, a 15.5 day mean reduction in
length of stay (0.046 t-test) with studies undertaken by
Nabower et al. and Didiodato et al. showing similar reduction
in LOS [12,13].Economic analysis
The costs for performance of laboratory testing com-
prised materials and the attributable pro rata medical sci-
entist salaries. The direct costs of analysis of 94 CSF
samples before introduction of the FilmArray was V2,800
(comprising consumables costings of approximately V750
with the remained being labour), while adoption of the
FilmArray resulted in an increase in actual costs of V12,480
(which was primarily consumables). However, this increase
is offset by potential reduction of length of hospital stay
and reduced duration of empiric treatment. Specifically, for
instance, based on the paediatric patient cohort alone there
would be a net saving of over V114,000, while extrapolating
reductions in duration of stay and empiric treatment col-
lectively in relation to all patients for whom CSF analysis
was requested the potentially accruable savings exceed V2
Million.
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In the context of requirements for rapid and accurate
diagnosis of meningitis/encephalitis (M/E) to promote suc-
cessful patient outcomes, this report describes an evaluation
of the FilmArray meningitis/encephalitis Panel (MEP), a
multiplexed PCR test for simultaneous, rapid detection of
pathogens directly from cerebrospinal fluid (CSF) samples. To
summarise, 94 prospectively collected CSF specimens from
patients with clinical suspicion of infective M/E underwent
testing for 14 pathogens simultaneously, including Escherichia
coli, Haemophilus influenzae, Neisseria meningitidis, and
Varicella zoster. MEP demonstrated 95% agreement with cur-
rent PCR methods, resulting in 16 diagnosed cases of M/E.
Typically, the FilmArray MEP results were delivered within
approximately one hour, contrasting with current practices
taking up to 5.6 days. Given the significant morbidity and
mortality associated with delayed diagnosis of central nervous
system infections, the FilmArray MEP is a useful addition to
the diagnostic capabilities of a clinical microbiology
department.
All causes of M/E can present with similar symptoms; yet
bacterial, viral or fungal involvement requires distinct
treatment strategies. Not surprisingly then, rapid and accu-
rate diagnosis continues to attract considerable attention,
with investment in molecular technologies and antimicrobial
stewardship targeting reduction in duration of empiric
treatment while enhancing patient outcomes. Through that
lens, emphasis has been placed on the fact that although not
especially labour intensive or time consuming, conventional
processes of microscopy and culture for microbiological
analysis of CSF has relatively poor diagnostic accuracy and
reliability. For example, in the United Kingdom a study of 103
patients with clinically defined meningococcal meningitis
resulted in only 13% positive CSF cultures [4]. This inaccuracy
has been attributed somewhat to administration of empiric
antimicrobials prior to lumbar puncture sampling, effectively
sterilising the CSF sample or at least reducing the microbial
load to levels below detection possible using conventional
culturing techniques [4,14]. This observation has been con-
firmed in reports such as that by Khater & Elabd [14], whereby
positive PCR results were demonstrated in 36 of 40 CSF sam-
ples, which had been found to be culture negative. With a
recent history of adoption of molecular diagnostic tech-
nologies and their effective implementation in outbreak
management [15,16] the objective of this new study was to
evaluate multiplex PCR, the FilmArray MEP, with regard to
diagnostic accuracy compared with current routine methods
of culture/microscopy/Gram stain and compared with sin-
gleplex bacterial and viral PCR services provided by Irish
centralised reference laboratories.
Notably, there was no statistical variation between sen-
sitivity results achievable through current conventional
techniques and the FilmArray MEP. In summary, there were
19 positive pathogen detections using the FilmArray MEP
while 18 pathogen detections were recorded using the
comparative reference methods, with viral pathogens
accounting for 68% of positive FilmArray MEP detections.
The FilmArray MEP detected at least one pathogen in 20%
(19/94) of CSF specimens. These included enterovirus,
N. meningitidis, Varicella zoster virus and Herpes simplexvirus 1. Among the multiplex PCR positive cases, enterovirus
was detected at the highest incidence of 7 cases (44%). This
result is similar to that found by Leber et al. [11] at 38%,
along with Desmond et al. [17] who have reported enter-
ovirus as the most common cause of viral meningitis in the
United States with an estimated 75,000 cases annually. The
second highest occurring agent detected by multiplex PCR
was N. meningitidis in 4 cases (25%). All 4 positive cases
were from an adult cohort and all were identified in the
reference laboratory as N. meningitidis serogroup C. Of
interest, the introduction in Ireland of the MenC vaccine for
infants and adolescents in the late 1990s can account for
the higher rate of pathogen positivity in the older cohort
with no positive cases identified in those <18 years [18].
However, we have reported elsewhere that the FilmArray
MEP can be used effectively in the analysis of paediatric
samples, albeit not CSF-derived, for effective detection of
N. meningitidis [19]. Overall, in our hands, the multiplex
PCR demonstrated sensitivity and specificity lower than
found by both Leber et al. (100%) [11] and von Allmen et al.
(100%, 99%) [20]. Despite this, the FilmArray MEP and PCR-
based results obtained from the national bacterial reference
laboratory correlated well. Indeed, the sensitivity results
were identical, albeit that the specificity of FilmArray MEP
was lower than anticipated at 80%.
Conversely though, the FilmArray MEP was less sensitive in
detection of viral nucleic material than the Irish National Viral
Reference Laboratory, but where detected the identification
proved as accurate. More specifically, two CSF samples refer-
red to the National Virus Reference Laboratory were positive
for Human herpes virus 6, while not detected by the
FilmArray MEP. This highlights the limitation of the assay for
detection of HHV-6 compared with the reference laboratory.
Analogously, the FilmArrayMEP identified Human herpes virus
6 in one sample that was not detected at the central labo-
ratory. However, the positive result did not correlate with
clinical presentation. The clinical significance of HHV-6 in
particular requires close clinical correlation to determine its
significance. HHV-6 detection in the CSF may indicate primary
infection, secondary reactivation, or the presence of latent
virus. Also, integration of HHV-6 DNA into human chromosomes
has been identified in approximately 1% of the human pop-
ulation [21]. Results should always be interpreted in con-
junction with other clinical, laboratory, and epidemiological
information. According to Slenker et al. caution should be
taken before attributing CNS disease to HHV6 when a positive
result is identified [22].
Given acceptable sensitivity and specificity, the most
notable result related to turnaround time for tests; the
FilmArray MEP was found to enable actionable results within
wone hour compared to 5.6 days for return of results from the
reference services. At the time of this study, positive results
only were communicated (verbally) to the duty clinical
microbiologist on the same day as the test result was author-
ised at the reference laboratories. Negative results were
mailed in hardcopy form. There now exists a secure electronic
information transport service for the prompt return of all
authorised results; both positive and negative.
Whether positive or negative, FilmArray results represent a
potential for clinicians to make relatively quicker decisions
regarding patients’ clinical management, including
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influence whether a patient merits admission from the ED, for
example in the setting of a Enteroviral-positive result. How-
ever, there is a need to perform longitudinal studies to deter-
mine the full impact of the FilmArray MEP on cost savings
encompassing antimicrobial savings, other diagnostic tests as
well patient outcomes and patient satisfaction. The outcomes
of both retrospective chart reviews and prospective patient
management were promising, with considerable reduction of
avoidable hospitalisation (mean >15 days) with associated
actual direct economic savings exceedingV100,000 that can be
extrapolated, based on whole cohort care, to potential savings
of more than V2 Million in unnecessary expenditure.
One limitation of this study is the relatively low number of
pathogens identified from clinical CSF samples allowing for
direct comparison with the reference method. It does, how-
ever, highlight the potential, as with any conventional PCR
based technique, for false positive results due to possible
sample contamination. This would reinforce the requirement
for strict laboratory procedures with “bench-top” molecular
platforms, particularly if the instrument becomes a point-of-
care test in an emergency departmental setting. Regardless
of the clinical significance of a positive result for HHV-6, in this
study the FilmArray MEP panel demonstrated inferior sensi-
tivity compared to the reference laboratory method. The
inclusion of data on estimated cost-savings is a strength of this
study, although limited to the paediatric cohort only and
potentially under-estimated overall cost savings. The retro-
spective nature of the study enabled collation of turnaround
times, which helped facilitate development of a business case
for implementation of the apparatus in routine diagnostic
service. Anecdotally, since its introduction locally into routine
CSF diagnostics, the feedback from medical staff has been very
positive, especially pertaining to turnaround times and impact
on antimicrobial stewardship. It is also noteworthy that actual
utilisation of the FilmArray MEP in practice has since
changed. Rather than reflex testing based on WCCs/differ-
ential, the FilmArray MEP is now employed based on clinical
suspicion of meningitis/encephalitis.
In summary, our findings suggest that there is merit in con-
sidering use of the FilmArray MEP in routine CSF analysis.
However, its adoption should parallel continuation of conven-
tional culture-based testing as the new instrument does not
allow antimicrobial sensitivity testing or, indeed, high-
throughput testing due to its capacity being limited to one
CSF sample.Funding
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